跳到正文
原文
Medical Xpress·· 22 天前AI 评分57

CRISPR 技术提升 utrophin 蛋白逆转肌营养不良

Halting muscular dystrophy with a 'backup' protein

AI 导读

研究人员利用 CRISPR 基因编辑技术提升 utrophin 蛋白,成功逆转 Duchenne 肌营养不良模型,为治疗该疾病提供了新方法。

正文
Stopping muscular dystrophy with a 'backup' protein
Graphical abstract. Credit: Molecular Therapy Advances (2026). DOI: 10.1016/j.omta.2026.201857

A new use of CRISPR gene editing has halted and even reversed the progression of a model of Duchenne muscular dystrophy, according to work led by scientists at the Perelman School of Medicine. The technique boosted a protein, utrophin, as a stand-in to take on the job of a different protein, dystrophin, which helps maintain healthy muscles and is in short supply in those with muscular dystrophy.

This work is published in Molecular Therapy Advances.

"Unfortunately, there are currently no safe and effective therapies that can cure Duchenne muscular dystrophy, or even treat everyone with the disease equally," says senior author Tejvir S. Khurana, a professor of physiology and a member of the Pennsylvania Muscle Institute. "But we believe that combining a pair of delivery systems already in use has great therapeutic potential and could lead to a significant change in how we treat this disease."

Duchenne muscular dystrophy affects roughly one in 5,000 children and typically leads to their death in their 20s. It is caused by a mutation in the DMD gene, which is responsible for creating the dystrophin protein and its associated partner proteins.

Without these proteins present to maintain and repair muscles during typical movements, muscle cells break down, turning to scar tissue. That results in progressive weakening and loss of muscles all over the body. However, in the absence of dystrophin, a significant amount of utrophin can actually take over what dystrophin is usually tasked with.

The issue has been how to get enough utrophin produced to adequately stand in.

The system that Khurana and his team used combined the expertise of Drew Weissman, the Roberts Family Professor in Vaccine Research, who won the Nobel Prize in 2023 for his work in developing mRNA systems that code the body's cells to produce certain proteins, and that of Michael Mitchell, the Hibbert Professor of Bioengineering in Penn Engineering, who developed a delivery system that uses fatty compounds—called lipid nanoparticles—to encase and bring cargo to targeted cells.

Moving forward, Khurana and colleagues from Penn Medicine and Children's Hospital of Philadelphia are working on new and different forms of gene editing that could be more precise and efficient in addressing utrophin production. They're also testing other potential delivery methods for the treatment.

More information

Trinath Ghosh et al., Functional improvement of dystrophic muscle by utrophin gene editing, Molecular Therapy Advances (2026). DOI: 10.1016/j.omta.2026.201857

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Halting muscular dystrophy with a 'backup' protein (2026, October 29) retrieved 29 October 2026 from https://medicalxpress.com/news/2026-10-halting-muscular-dystrophy-backup-protein.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com